The Lubrizol Corp. has acquired Bavaria Medizin Technologie GmbH (BMT). This acquisition expands Lubrizol’s expertise in precision thermoplastic extrusion and product development, for the global medical device and pharmaceutical industries. 

BMT developed the first commercial drug-coated balloon, the Paccocath catheter. Today, BMT holds over 50 patents and continues to innovate through self-funded R&D projects, as well as contract R&D services. BMT’s experience in the drug-coated balloon (DCB) space aligns with Lubrizol’s pharmaceutical CDMO business and positions Lubrizol as a partner for developing next generation DCBs.
 
“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the Health business of Lubrizol Life Science. “Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services.”